PHARMA TARIFFS
Pharma & healthcare funds top mutual fund return charts with over 19% gains. Should investors invest now or wait for a correction?
Pharma and healthcare mutual funds have topped return charts in 2026 with over 19% gains. While strong sector growth supports the outlook, experts caution against chasing the rally and advise investors to assess valuations, risks and portfolio exposure.
Samvat 2083 outlook: 8 triggers that could turn Sensex, Nifty correction into a rally by next Diwali
Indian equities enter Samvat 2083 after a correction that has made valuations more attractive, but a sustained rally will depend on several triggers. Falling crude oil prices, easing inflation, an earnings recovery, FII buying, an India-US trade deal and continued domestic liquidity could shape the market's trajectory over the next year.
Muhurat Trading 2026: Sensex falls 29 points, Nifty below 25,000 as market snaps 6-day explosive rally on Diwali. What lies ahead in Samvat 2083?
The Indian stock market experienced sharp gains during the Muhurat Trading session on Diwali. Sensex increased by 350 points, surpassing 81,380, indicating strong investor interest. Nifty 50 rose over 80 points, crossing 23,100 as well. Tata Steel, Sun Pharma, BEL, and HDFC Bank contributed to these gains, while some stocks faced losses. Overall, the market breadth remained positive, with more advances than declines.
Global Market Today: Asian stocks join US selloff as AI slump deepens
South Korea’s tech-heavy Kospi Index slid 8.8% in early trading, triggering a circuit breaker, with chipmakers Samsung Electronics Co. and SK Hynix Inc. both plunging more than 9%. Japan’s benchmark Nikkei 225 Stock Average lost 6.2%, while the MSCI Asia Pacific Index declined 2.9%. Futures pointed to losses in Taiwan, Hong Kong and China.
Ahead of Market: 10 things that will decide stock market action on Friday
Indian markets staged a powerful rally, with Sensex jumping 2,009 points and Nifty gaining 576 points. Improved global sentiment, easing crude prices, US midterm election results, foreign investor buying and strong Q2 earnings lifted market capitalisation above Rs 500 lakh crore.
Market wrap: Bajaj Finance, Shriram Finance, Apollo Hospital, ONGC top gainers and losers on Nifty and Sensex on Thursday
Indian equity markets staged a strong rally on Thursday, with the Sensex surging over 2,000 points and the Nifty jumping 576 points amid optimism following the US midterm election results. Bajaj Finance, Shriram Finance and M&M led the gainers, while Apollo Hospitals and ONGC featured among the top laggards.
- Go To Page 1
Reset will keep India busy as Trump’s midterm loss redraws US politics
The recent US midterm elections have significant implications for international relations and the economy. Incoming policies may impact trade agreements between India and the US, affecting both countries' economies. Additionally, potential conflicts involving Iran could influence energy prices in India, creating economic uncertainty. The evolving political landscape in Washington will require India to adjust its diplomatic strategies.
Ahead of Market: 10 things that will decide stock market action on Thursday
Indian markets extended their rally, with Sensex gaining 384 points to 77,301 and Nifty rising 150 points to 23,961, marking two-month highs. Positive sentiment, strong earnings, festive demand and buying across mid- and small-caps supported gains.
Diwali 2026: 77 stocks knock down D-St bears to deliver multibagger returns of up to 4,700% in a year
With Diwali 2026 on the horizon, 77 stocks have thrived despite market fluctuations, marking exceptional returns. Mrugesh Trading showcases an astonishing gain of 4,657%, while Axis Solution follows closely with 1,081%. Other strong performers are Sterlite Technologies and Cupid, each demonstrating impressive growth. Analysts are hopeful for a market rebound thanks to falling crude oil prices, which could positively impact sectors such as automotive, capital goods, and pharmaceuticals.
Climate platform Two Point O raises $10 million led by Transition Venture Capital
The company plans to enter battery energy storage while expanding its existing offerings in solar power, energy efficiency, and wastewater treatment. It will also target customers in sectors such as data centres, automobile manufacturing, pharmaceuticals, and healthcare, where energy and water consumption are significant operating costs.
India, Mexico begin talks for trade pact; aim to boost commerce, investments
India and Mexico have initiated negotiations for a preferential trade agreement to enhance bilateral trade and investment. The agreement aims to create new economic opportunities while addressing market access, customs procedures, and trade facilitation. Discussions included organising a Mexican business mission to India in early 2027 to improve commercial ties. India had a trade surplus with Mexico, largely due to exports in autos and pharmaceuticals.
Why did market fall today? Sensex falls 353 points, Nifty closes below 22,700 despite Jio’s solid debut; 4 triggers spooking D-Street
In a challenging session, the Indian stock market dipped into the red due to increased oil prices and a slump in IT stocks. Jio Platforms’ promising launch couldn't counter the broader fears stemming from escalating conflicts in the Middle East. Major indices dropped sharply, impacted by worries about inflation and fluctuating bond yields.
China says ready to address each other's concerns after Sitharaman flags trade barriers
China said it was ready to work with India to allay its concerns of rising trade imbalance. Finance Minister Nirmala Sitharaman said the trade imbalance was due to China's restrictions in market access to Indian goods and services. She said that India has not resorted to punitive tariffs to reign in large trade imbalances and prefers negotiations despite the process being time-consuming.
Apollo, Max Health, other hospital stocks rally up to 5% despite cancer drug price caps. Why Jefferies stays bullish
Hospital stocks rose up to 5% after the government capped trade margins on non-scheduled anti-cancer drugs at 30%, potentially reducing medicine prices by 70%. Jefferies and Emkay expect manageable earnings impacts, despite near-term margin pressures. Jefferies favours Fortis, Manipal, Apollo, Max Healthcare and Medanta, citing strong demand and attractive valuations.
CPHI Milan: Beyond generics, how Indian pharma is rewriting its global playbook
At CPHI Milan, Indian pharma players are looking beyond traditional exports, using partnerships, licensing, CDMO, and differentiated products to expand their global footprint as geopolitical and supply-chain risks reshape the industry.
When nothing is cheap, winners may come from any corner: 19 stocks with downside to upside potential of -28% to plus 22%
Because each pharma company took a different road, they no longer rise and fall together. Where any one of them stands in 10 years depends on what it chose in the last five or six. So, one name can do wonderfully while the one sitting next to it does very little. Stock Reports Plus, powered by Refinitiv, is a comprehensive report that evaluates five key components of 4,000+ listed stocks – earnings, fundamentals, relative valuation, risk, and price momentum – to generate standardised scores. The simple average of the above-mentioned five component ratings is normally distributed to reach an average score.
Nifty 50 companies likely to log strong double-digit growth in Q2
Revenue and net profit of Nifty 50 companies are projected to grow by nearly 20% year-on-year. Analysts note that performance is driven by sectors like automobiles, banking, and oil. Operating margins, however, might contract slightly due to input cost pressures and inflation. Key sectors show varied conditions, balancing strong demand against potential challenges. Overall, medium to long-term outlook remains optimistic, despite some near-term volatility.
Germany's Bayer to invest $2.2 billion in US pharma site
Bayer has announced a significant investment of $2.2 billion to establish a new pharmaceutical site in New Albany, Ohio. This project follows over $7 billion in investments by Bayer in US pharmaceutical research and development. The facility aims to focus on critical areas including cancer, heart, and kidney care. It is expected to create around 600 permanent jobs and 1,500 construction jobs during its development.
Fortis, Apollo, other hospital stocks slump up to 10% in 2 days after SC questions steep markups. Buying opportunity?
Hospital stocks extended losses for a second session after the Supreme Court questioned steep markups on cancer drugs and raised concerns over hospitals requiring patients to buy medicines from their own or designated pharmacies.
FIIs dump telecom for 8th straight month, outflows cross Rs 32,000 crore. Are stocks set for rebound?
Foreign portfolio investors have dumped Indian telecom stocks for the eighth consecutive month, pulling out over Rs 32,000 crore in CY26. Heavy 5G capex, delayed tariff hikes, and legal dues weigh on cash flows, leaving market participants questioning if a stock rebound is near.
India rejects Australia's high sugar subsidy claims at WTO
Australia referring to the WTO panel in the India sugar and sugarcane dispute which found in 2021 that India’s sugar support regime was inconsistent with its WTO obligations and subsidies were in excess of levels permitted under WTO rules.
Sun Pharma, Aurobindo Pharma, other stocks in focus as Trump exempts India from 100% tariffs on some speciality drugs
Indian pharma stocks, including Sun Pharma and Aurobindo Pharma, are in focus after the US exempted India and 19 other countries from 100% tariffs on certain patented specialty pharmaceuticals and ingredients. Eligible products include rare-disease drugs, gene and cell therapies, and infertility treatments. Generic medicines remain outside the Section 232 tariffs.
Market veterans favour value plays over crowded, expensive themes
Market experts project cautious optimism for Indian equities as valuations become less demanding and earnings growth aligns. Large-cap stocks appear more favorable compared to mid- and small-caps, which require prudence. Preferred sectors include financials, manufacturing, and consumer discretionary, while technology remains divisive. Investors are advised to avoid slow-growth sectors and overpriced mid-caps. Overall, low-teens returns are anticipated amid various global risks and economic conditions.
US exempts India and 19 nations from 100% tariff on certain speciality drugs: Report
The United States has announced it will exempt certain speciality drugs and ingredients imported from India and 19 other countries from tariffs. This decision follows US President Donald Trump's proclamation imposing a 100% tariff on specified patented pharmaceuticals. Drugs intended for rare diseases and infertility, along with their components, will qualify for the zero-tariff treatment. The exemption applies to 20 other jurisdictions that have trade agreements with the US.
MF Tracker: HDFC Pharma & Healthcare Fund tops equity MFs at 25% in 1 year. Should investors chase the rally?
HDFC Pharma and Healthcare Fund recorded an impressive 25% return in the last year, surpassing its category average across various time frames. The robust performance is primarily due to heightened demand for generic drugs and recent FDA approvals. Investors are advised to steer clear of merely chasing past successes and instead focus on a sustainable long-term strategy.
Behind the Modi-Xi border thaw, India's dependence on Chinese imports, especially rare earths, keeps deepening
India faces a significant trade deficit with China, importing substantially more goods than it exports. Chinese firms offer superior price and tech competitiveness, impacting Indian industries. India relies heavily on China for critical inputs like rare earths, affecting various sectors.
CAS chaos: Sensex ends in red as indicative price falls 270 points in 5 minutes, Nifty above 23,250
Indian stock markets showed divergence on Thursday as Sensex closed lower while Nifty ended higher. Sensex experienced volatility during the closing auction session, leading to its decline. Broader markets like Nifty Midcap and Smallcap indices saw gains after recent corrections. Investor sentiment remains cautious due to global tensions and potential rate hikes. Mid and small-cap stocks continue to outperform, favoring companies with strong fundamentals.
A weekend in New Delhi: At BRICS, Modi and India provided an adroit demonstration of tactically gathering a motley crew
The recent BRICS summit hosted twenty nations, fostering debate and wide interpretation of its joint statement. This gathering served as a protest forum against global economic instability and institutional failures. India's diplomacy showcased its appeal as a stable pillar amidst geopolitical challenges. The summit highlighted crucial supply chains and commodity linkages within BRICS family countries. India's engagement demonstrates the need for intricate networks and tactical arrangements in global affairs.
BRICS Summit 2026: Putin’s India visit puts trade, defence and Ukraine peace efforts in focus
Russian President Vladimir Putin arrived in India for a three-day visit. He will meet Prime Minister Narendra Modi and attend the BRICS summit. Bilateral trade, investment, energy, and defense ties will dominate the agenda. The Russia-Ukraine war and peace efforts are also expected to be discussed. Putin's participation marks his first in-person BRICS summit outside Russia since the war.
Load More
